Differential changes in Aβ42 and Aβ40 with age

Journal of Alzheimer's Disease

Volumn 40, Issue 3, 2014, Pages 727-735

  Miners, James Scott ^a   Jones, Ruth ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

aging; amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GUANIDINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADOLESCENT; ADULT; AGE; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN; BRAIN LEVEL; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; VERY ELDERLY; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; YOUNG ADULT;

EID: 84901941810     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132339     Document Type: Article

References (59)

1. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
2. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid- peptides differentially affect neuronal viability. J Biol Chem 277, 32046-32053. (Pubitemid 34969015)
3. Gravina SA, Ho LB, Eckman CB, Long KE, Otvos L,Younkin LH, Suzuki N, Younkin SG (1995) Amyloid- protein (A) in Alzheimer's disease brain - biochemical and immunocytochemical analysis with antibodies specific for forms ending at A40 or A42(43). J Biol Chem 270, 7013-7016.
4. IwatsuboT, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) visualization of a-42(43) and a-40 in senile plaques with end-specific a- monoclonals - evidence that an initially deposited species is A42(43). Neuron 13, 45-53.
5. Pauwels K, Williams TL, Morris KL, Jonckheere W, Vandersteen A, Kelly G, Schymkowitz J, Rousseau F, Pastore A, Serpell LC, Broersen K (2012) Structural basis for increased toxicity of pathological A(42):A(40) ratios in Alzheimer disease. J Biol Chem 287, 5650-5660.
6. Wang J, Dickson DW, Trojanowski JQ, Lee VMY (1999) The levels of soluble versus insoluble brain A distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158, 328-337. (Pubitemid 29382824)
7. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the etiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
8. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy- Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870. (Pubitemid 26296755)
9. Wolfe MS (2007) When loss is gain: Reduced presenilin proteolytic function leads to increased A 42/A 40 - Talking Point on the role of presenilin mutations in Alzheimer disease. Embo Rep 8, 136-140. (Pubitemid 46420840)
10. Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 21, 479-505. (Pubitemid 28150671)
11. Selkoe DJ (1998) The cell biology of -amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8, 447-453.
12. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC (2004) -secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164, 719- 725. (Pubitemid 38364685)
13. van Helmond Z, Miners JS, Kehoe PG, Love S (2010) Higher soluble amyloid concentration in frontal cortex of young adults than in normal elderly or Alzheimer's disease. Brain Pathol 20, 787-793.
14. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on A, Alzheimer's A (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
15. van Helmond Z, Heesom K, Love S (2009) Characterisation of two antibodies to oligomeric A and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 176, 206-212.
16. van Helmond Z, Miners JS, Kehoe PG, Love S (2010) OligomericAin Alzheimer's disease: Relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 20, 468-480.
17. Barua NU, Miners JS, Bienemann AS, Wyatt MJ, Welser K, Tabor AB, Hailes HC, Love S, Gill SS (2012) Convectionenhanced delivery of neprilysin: A novel amyloid- degrading therapeutic strategy. J Alzheimers Dis 32, 43-56.
18. Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ (1997) Degradation of amyloid -protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem 272, 6641-6646. (Pubitemid 27118149)
19. Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi H, Yoshimura M, Sugihara S, Ihara Y (2000) Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid -protein accumulation in the human brain. Am J Pathol 157, 2093-2099.
20. Jan A, Gokce O, Luthi-Carter R, LashuelHA(2008) The ratio of monomeric to aggregated forms of A40 and A42 is an important determinant of amyloid- aggregation, fibrillogenesis, and toxicity. J Biol Chem 283, 28176-28189.
21. Placanica L, Zhu L, LiYM(2009) Gender- and age-dependent -secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS One 4, 1-9.
22. Funato H, Yoshimura M, Kusui K, Tamaoka A, Ishikawa K, Ohkoshi N, Namekata K, Okeda R, Ihara Y (1998) Quantitation of amyloid -protein (A) in the cortex during aging and in Alzheimer's disease. Am J Pathol 152, 1633-1640. (Pubitemid 28275021)
23. Hellstrom-Lindahl E, Ravid R, Nordberg A (2008) Agedependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with A levels. Neurobiol Aging 29, 210-221.
24. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of A amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866.
25. Nishimura M, Nakamura S, Kimura N, Liu L, Suzuki T, Tooyama I (2012) Age-related modulation of -secretase activity in non-human primate brains. J Neurochem 123, 21- 28.
26. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, DagnaBricarelli F, Scartezzini P, Bertolini S, Mann DMA, Tabaton M, Gambetti P (1996) Presence of soluble amyloid -peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2, 93-95.
27. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ (2013) Increased in vivo amyloid-42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5, 189-207.
28. Kumar-Singh S, Theuns J,Van Broeck B, Pirici D,Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased A42 and decreased A40. Hum Mutat 27, 686- 695.
29. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS -amyloid in Alzheimer's disease. Science 330, 1774.
30. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ (2012) Effects of age and amyloid deposition on A dynamics in the human central nervous system. Arch Neurol 69, 51-58.
31. Hawkes CA, Gatherer M, Sharp MM, Dorr A, Yuen HM, Kalaria R, Weller RO, Carare RO (2013) Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid- from the mouse brain. Aging Cell 12, 224-236.
32. Hawkes CA, Hartig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol 121, 431-443.
33. Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, Johanson CE, Silverberg GD (2011) Amyloid- transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS 8, 21.
34. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, Donahue JE, Johanson CE (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 69, 1034-1043.
35. Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE, Stopa EG, Johanson CE (2010) Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol 69, 98-108.
36. Holtzman DM, Mobley WC (1991) Molecular studies in Alzheimer's disease. Trends Biochem Sci 16, 140-144. (Pubitemid 121004421)
37. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL (1989) Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320, 1446- 1452. (Pubitemid 19143709)
38. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) - secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59, 1381-1389. (Pubitemid 35014802)
39. Miners JS, van Helmond Z, Kehoe PG, Love S (2010) Changes with age in the activities of -secretase and the a - degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol 20, 794-802.
40. Chen FS, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, Katayama T, Gu YJ, Sanjo N, Glista M, Rogaeva E,Wakutani Y, Pardossi-Piquard R, Ruan XY, Tandon A, Checler F, Marambaud P, Hansen K, Westaway D, St George-Hyslop P, Fraser P (2006) TMP21 is a presenilin complex component that modulates -secretase but not epsilon-secretase activity. Nature 440, 1208-1212.
41. Zhou SX, Zhou H, Walian PJ, Jap BK (2005) CD147 is a regulatory subunit of the -secretase complex in Alzheimer's disease amyloid -peptide production. Proc Natl Acad Sci U S A 102, 7499-7504. (Pubitemid 40741000)
42. He G, Luo WJ, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F,Wennogle LP, Greengard P (2010) -secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95-U129.
43. Hussain I, Fabregue J, Anderes L, Ousson S, Borlat F, Eligert V, Berger S, Dimitrov M, Alattia JR, Fraering PC, Beher D (2013) The role of -secretase activating protein (GSAP) and imatinib in the regulation of -secretase activity and amyloid- generation. J Biol Chem 288, 2521-2531.
44. Guix FX, Wahle T, Vennekens K, Snellinx A, Chavez- Gutierrez L, Ill-Raga G, Ramos-Fernandez E, Guardia- Laguarta C, Lleo A, Arimon M, Berezovska O, Munoz FJ, Dotti CG, De Strooper B (2012) Modification of - secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease. Embo Mol Med 4, 660-673.
45. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L (1988) Clinicopathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38, 1682-1687. (Pubitemid 18265029)
46. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid- protein assembly in the brain impairs memory. Nature 440, 352- 357.
47. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid- protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
48. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid -protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol 572, 477-492.
49. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble A (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271, 4077-4081.
50. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862. (Pubitemid 29426831)
51. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's diseaseaffected brain: Presence of oligomeric A ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100, 10417-10422. (Pubitemid 37071893)
52. Maclean CJ, Baker HF, Ridley RM, Mori H (2000) Naturally occurring and experimentally induced -amyloid deposits in the brains of marmosets (Callithrix jacchus). J Neural Transm 107, 799-814. (Pubitemid 30468267)
53. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH (2013) Brain amyloid- oligomers in ageing and Alzheimer's disease. Brain 136, 1383-1398.
54. Kumar S, Walter J (2011) Phosphorylation of amyloid (A) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease. Aging (Albany NY) 3, 803-812.
55. Hartig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J (2010) Concomitant detection of -amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. J Chem Neuroanat 40, 82-92.
56. Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, Mc Donald JM, Wullner U, Glebov K, Heneka MT, Walsh DM, Zweckstetter M, Walter J (2011) Extracellular phosphorylation of the amyloid -peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J 30, 2255-2265.
57. DeKosky ST, Abrahamson EE, Ciallella JR, Paljug WR,Wisniewski SR, Clark RS, Ikonomovic MD (2007) Association of increased cortical soluble a42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 64, 541-544. (Pubitemid 46588343)
58. Duron E, Hanon O (2008) Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis 101, 181-189. (Pubitemid 351739263)
59. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, KukullWA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L (2003) Depression as a risk factor for Alzheimer disease: The MIRAGE Study. Arch Neurol 60, 753-759. (Pubitemid 36569895)